Sanjeev Saksena1,2, April Slee3,4, Marwan Saad3,4. 1. Electrophysiology Research Foundation, 161 Washington Valley Road, Suite 201, Warren, NJ, 07059, USA. cmenj@aol.com. 2. Rutgers'- Robert Wood Johnson Medical School, Piscataway, NJ, USA. cmenj@aol.com. 3. Electrophysiology Research Foundation, 161 Washington Valley Road, Suite 201, Warren, NJ, 07059, USA. 4. Rutgers'- Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Abstract
BACKGROUND: We examined the long-term (≥ 5 years) outcomes of dual-site atrial pacing (DAP) when added to background antiarrhythmic drugs (AADs) and/or ablation in patients with refractory atrial fibrillation (AF) and heart failure (HF). METHODS: Seventy-three patients with HF (mean NYHA HF class of 2.5) and AF refractory to AADs and/or ablation were implanted with DAP systems to achieve biatrial electrical and mechanical resynchronization (ART) and rhythm control (RC). RESULTS: Thirty-eight patients with refractory AF and HF with preserved ejection fraction (HFpEF) and 35 with reduced ejection fraction (HFrEF) were enrolled. HFpEF patients had higher left ventricular ejection fraction compared to HFrEF (53 ± 5 vs. 31 ± 10% p < 0.001). Median follow-up for survival was 9.3 years (mean 9.0 years, SE 0.63) and was similar across subgroups (p = 0.127). After DAP, 87% maintained RC with improvement in NYHA HF class (mean 1.8) at 3 years. RC was similar in HFpEF compared with HFrEF patients (89 vs. 85% respectively, p = NS) and in paroxysmal versus persistent AF (90 vs. 85% respectively, p = NS). Total survival was superior in HFpEF compared HFrEF patients (75% in HFpEF vs. 45% in HFrEF at 5 years, and 60% in HFpEF vs. 34% in HFrEF at 10 years, p = 0.036). Survival trended to be better in patients with RC than those without RC (75 vs. 54% respectively at 5 years, p = .13). CONCLUSIONS: ART using DAP as add on therapy improved HF and established long-term RC in many patients with HFrEF and HFpEF with refractory AF. Long-term survival rates were superior in HFpEF than HFrEF.
BACKGROUND: We examined the long-term (≥ 5 years) outcomes of dual-site atrial pacing (DAP) when added to background antiarrhythmic drugs (AADs) and/or ablation in patients with refractory atrial fibrillation (AF) and heart failure (HF). METHODS: Seventy-three patients with HF (mean NYHA HF class of 2.5) and AF refractory to AADs and/or ablation were implanted with DAP systems to achieve biatrial electrical and mechanical resynchronization (ART) and rhythm control (RC). RESULTS: Thirty-eight patients with refractory AF and HF with preserved ejection fraction (HFpEF) and 35 with reduced ejection fraction (HFrEF) were enrolled. HFpEF patients had higher left ventricular ejection fraction compared to HFrEF (53 ± 5 vs. 31 ± 10% p < 0.001). Median follow-up for survival was 9.3 years (mean 9.0 years, SE 0.63) and was similar across subgroups (p = 0.127). After DAP, 87% maintained RC with improvement in NYHA HF class (mean 1.8) at 3 years. RC was similar in HFpEF compared with HFrEF patients (89 vs. 85% respectively, p = NS) and in paroxysmal versus persistent AF (90 vs. 85% respectively, p = NS). Total survival was superior in HFpEF compared HFrEF patients (75% in HFpEF vs. 45% in HFrEF at 5 years, and 60% in HFpEF vs. 34% in HFrEF at 10 years, p = 0.036). Survival trended to be better in patients with RC than those without RC (75 vs. 54% respectively at 5 years, p = .13). CONCLUSIONS: ART using DAP as add on therapy improved HF and established long-term RC in many patients with HFrEF and HFpEF with refractory AF. Long-term survival rates were superior in HFpEF than HFrEF.
Entities:
Keywords:
Atrial fibrillation; Atrial resynchronization; Heart failure; Heart failure with preserved systolic function
Authors: Lars Køber; Karl Swedberg; John J V McMurray; Marc A Pfeffer; Eric J Velazquez; Rafael Diaz; Aldo P Maggioni; Viatcheslav Mareev; Grzegorz Opolski; Frans Van de Werf; Faiez Zannad; Georg Ertl; Scott D Solomon; Steven Zelenkofske; Jean-Lucien Rouleau; Jeffrey D Leimberger; Robert M Califf Journal: Eur J Heart Fail Date: 2006-02-28 Impact factor: 15.534
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer Journal: J Am Coll Cardiol Date: 2006-04-27 Impact factor: 24.094
Authors: Philip J Gentlesk; William H Sauer; Edward P Gerstenfeld; David Lin; Sanjay Dixit; Erica Zado; David Callans; Francis E Marchlinski Journal: J Cardiovasc Electrophysiol Date: 2006-11-01
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Luigi Di Biase; Prasant Mohanty; Sanghamitra Mohanty; Pasquale Santangeli; Chintan Trivedi; Dhanunjaya Lakkireddy; Madhu Reddy; Pierre Jais; Sakis Themistoclakis; Antonio Dello Russo; Michela Casella; Gemma Pelargonio; Maria Lucia Narducci; Robert Schweikert; Petr Neuzil; Javier Sanchez; Rodney Horton; Salwa Beheiry; Richard Hongo; Steven Hao; Antonio Rossillo; Giovanni Forleo; Claudio Tondo; J David Burkhardt; Michel Haissaguerre; Andrea Natale Journal: Circulation Date: 2016-03-30 Impact factor: 29.690
Authors: Maja Cikes; Brian Claggett; Amil M Shah; Akshay S Desai; Eldrin F Lewis; Sanjiv J Shah; Inder S Anand; Eileen O'Meara; Jean L Rouleau; Nancy K Sweitzer; James C Fang; Sanjeev Saksena; Bertram Pitt; Marc A Pfeffer; Scott D Solomon Journal: JACC Heart Fail Date: 2018-07-11 Impact factor: 12.035